Descripción de la empresa
Cognition Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of small molecule therapeutics designed to target age-related degenerative diseases and disorders affecting the central nervous system and the retina. The company functions within the broader healthcare sector, specifically occupying the biotechnology industry, a domain characterized by high capital intensity and significant reliance on successful clinical trial outcomes to generate future commercial revenue. As of the latest reporting period, the enterprise holds a market capitalization of $73.04M and maintains an employee count of 14, reflecting a lean organizational structure typical of early-stage research-focused firms. These financial figures indicate that the company is currently in a pre-revenue or early-stage development phase, where the market capitalization primarily reflects the potential value of its pipeline assets rather than established cash flows from commercial sales.
Salud financiera
The financial statements for Cognition Therapeutics, Inc. show a trailing twelve-month (TTM) revenue figure listed as N/A, while the net income for the same period stands at a loss of $-23,487,000, and the EBITDA is recorded at $-47,763,000. The substantial gap between the reported revenue (N/A) and the significant negative net income reveals a cost structure dominated by research and development expenditures, clinical trial costs, and general administrative expenses that exceed any current operating income. The company's free cash flow is reported at $-31,391,500, which indicates a heavy cash burn rate typical for clinical-stage biotechs and suggests limited financial flexibility without additional capital raising or funding events in the near future. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, indicating that the company has not yet achieved profitability from its product candidates and that all revenue generated (if any) is consumed by direct costs and operating expenses. In terms of liquidity and leverage, the company holds $36.81M in cash against total debt of $638,000, resulting in a debt-to-equity ratio of 1.86, which presents a mixed picture of low absolute debt obligations but a high leverage ratio relative to equity. The current ratio is reported at 3.45, suggesting that the company possesses a robust level of short-term assets relative to its current liabilities, providing a buffer for operational continuity despite the cash burn. Finally, the return on equity is -88.6% and the return on assets is -76.0%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a common characteristic for companies in the clinical development stage that have not yet commercialized their lead products.
Evaluación de valoración
Valuation metrics for Cognition Therapeutics, Inc. reflect the challenges faced by pre-commercial entities, with a trailing P/E ratio listed as N/A and a forward P/E of -2.72. The discrepancy between the missing trailing P/E and the negative forward P/E implies that the market is valuing the company based on future earnings expectations that are currently projected to be negative, highlighting the speculative nature of the investment. The price-to-book ratio is stated at 2.12, indicating that the market is pricing the company at a significant premium above its tangible book value, likely driven by the perceived potential of its intellectual property and pipeline candidates. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.77, further underscore that traditional valuation multiples are not applicable due to the lack of positive earnings and established sales revenue. The stock's trading range over the past year spans a 52-week high of $3.83 and a 52-week low of $0.22, providing a wide volatility band within which the current price must be interpreted relative to these extremes. The beta value is recorded at 1.40, which signifies that the stock price exhibits higher volatility relative to the broader market, moving 40% more than the market index on average during periods of fluctuation.
Growth & Income
Growth metrics for Cognition Therapeutics, Inc. indicate a revenue growth year-over-year of N/A and an earnings growth year-over-year of N/A, reflecting the absence of commercial sales data typical for a clinical-stage biopharmaceutical company. Since revenue growth and earnings growth are both unavailable or negative in nature, there is no data to suggest that earnings are growing faster or slower than revenue, as the fundamental basis for such a comparison does not yet exist. As a non-dividend payer, the company does not distribute a dividend yield, which remains N/A, nor does it maintain a payout ratio, which is 0.0%, meaning that all available cash flow is theoretically retained or utilized for operational needs and research activities rather than distributed to shareholders. This reinvestment strategy is standard for the industry, as companies prioritize funding clinical trials and expanding their development pipeline over providing income to investors. The overall growth and income profile of Cognition Therapeutics, Inc. is currently defined by a reliance on future commercial success rather than current earnings growth or dividend income generation.